Filter
Period
Filter by
recent search
Showing: 1 – 05 of 153 Regulated Information
26 May 2023
26 May 2023
LinkedIn
Facebook
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
PARIS, FRANCE, 26 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Products for Human Use (CHMP)…
19 May 2023
19 May 2023
&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28111533/PR_final.jpeg "Share on LinkedIn")
LinkedIn
New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
PARIS, France, 8 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19th Annual European Neuroendocrine Tumor Society (ENETS) Conference, 10-11 March 2022, in Barcelona, Spain. Presentations include data from…
LinkedIn
10 May 2023
10 May 2023
LinkedIn
Ipsen : 2023 CSM – Formalities for making available preparatory documents to the Meeting
INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS’ MEETING OF 31 MAY 2023
27 April 2023
27 April 2023
LinkedIn
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023